WC
FPRX

Wexford Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Wexford Capital’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-112,700
Closed -$1.57M – 164
2018
Q3 		$1.57M Buy
+112,700
New +$1.68M 0.1% 88

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wexford Capital's FPRX Position: Q4 2018 in Review

Wexford Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2018, closing a stake of 112,700 shares — an estimated $1.57M sold.

Wexford Capital first reported a position in FPRX in Q3 2018 and held it in 1 quarter. The position peaked at $1.57M in Q3 2018. 116 funds tracked by Wall St. Rank hold FPRX as of Q4 2018.

  • Wexford Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Wexford Capital sold 112,700 Five Prime Therapeutics, Inc. shares in Q4 2018, an estimated $1.57M.
  • Wexford Capital first reported a position in Five Prime Therapeutics, Inc. in Q3 2018 and held it in 1 quarter.
  • Wexford Capital's Five Prime Therapeutics, Inc. position peaked at $1.57M in Q3 2018.
  • 116 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2018.

Based on Wexford Capital's 13F filing for Q4 2018, filed 14 Feb 2019.